Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)
← catalyst calendarSponsored by Jasper Therapeutics, Inc. (industry) · JSPR — their whole pipeline →.
Phase
Phase 1/2
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
87actual
Sites
23
Countries
Germany, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-29 | actual | When the study began enrolling |
| Primary completion | 2026-07-08 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-08 | actual | The whole study's end, after follow-up |
| First posted | 2023-12-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Spontaneous Urticaria
Interventions
- Drug: Briquilimab — also filed as JSP191
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFEvaluate the safety and tolerability of briquilimab
measured From signing the informed consent form (ICF) through end of trial (EOT) visit (up to 48 weeks)
Permalink · JSPR's whole pipeline · Catalyst calendar · Every registered study · What changed